How to Apply for a LUNGevity Grant

LUNGevity Awards for Translational Research

LUNGevity supports translational research in three tracks: career development, early detection, and targeted therapeutics.

Only the Career Development Award program was offered in 2019. Read about the funded projects here.

Career Development Awards

  • 3-year grants, totaling $300,000
  • Limit of one award per institution
  • Mentored awards

click here for details

Career Development Awards

LUNGevity’s Career Development Awards for Translational Research program was created to support future research leaders who will keep the field of lung cancer research vibrant with new ideas.

Applicants must be within the first five years of their faculty appointment. The Career Development Awards are mentored awards; a mentoring plan is part of the required submission.

Funded projects are expected to have a direct impact on the early detection of lung cancer or on the outcomes of lung cancer, or to provide a clear conceptual or experimental foundation for the future development of methods for early detection and/or individualized treatment, including through targeted therapy and immunotherapy.

Early Detection and Interception Award

LUNGevity Foundation is currently collaborating with Stand Up To Cancer and the American Lung Association (via LUNG FORCE) on two four-year projects (2018-2022) that focus on lung cancer interception: catching precancerous cells and blocking them from turning into cancer cells. The Thomas G. Labrecque Foundation is also investing in this collaboration. Two teams of interdisciplinary and multi-institutional researchers are being funded: a Lung Cancer Interception Dream Team, whose project is Intercept Lung Cancer Through Immune, Imaging, & Molecular Evaluation (InTIME), and a Lung Cancer Interception Translational Research Team, whose project is Blood-Based Early Interception of Lung Cancer.

Therapeutics Awards

LUNGevity’s Therapeutics Awards for Translational Research support research projects directed at individualized treatments, including targeted therapeutics and immunotherapy, that will make a difference in the clinical treatment and survival of patients.